Release of TNF-α from in vitro-stimulated monocytes is negatively associated with serum levels of apolipoprotein B in patients with type 2 diabetes

Scandinavian Journal of Immunology

Volumn 60, Issue 5, 2004, Pages 535-542

  Zykova, S N ^a   Svartberg, J ^b   Seljelid, R ^a   Iversen, H ^a   Lund, A ^a   Svistounov, D N ^a   Jenssen, T G ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SIMVASTATIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; LIPOPROTEIN METABOLISM; LYMPHOCYTE ACTIVATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

APOLIPOPROTEINS B; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MONOCYTES; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 8444221561     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0300-9475.2004.01509.x     Document Type: Article

References (35)

1. Leibovich SJ, Ross R. The role of the macrophage in wound repair. A study with hydrocortisone and antimacrophage serum. Am J Pathol 1975;78:71-100.
2. Zykova SN, Jenssen TG, Berdal M, Olsen R, Myklebust R, Seljelid R. Altered cytokine and nitric oxide secretion in vitro by macrophages from diabetic type II-like db/db mice. Diabetes 2000;49:1451-8.
3. Corica F, Allegra A, Corsonello A et al. Relationship between plasma leptin levels and the tumor necrosis factor-alpha system in obese subjects. Int J Obes Relat Metab Disord 1999;23:355-60.
4. Gonzalez F, Thusu K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome. Metabolism 1999;48:437-41.
5. Nilsson J, Jovinge S, Niemann A, Reneland R, Lithell H. Relation between plasma tumor necrosis factor-alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1998;18:1199-202.
6. Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6 tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 2000;67:291-300.
7. Woodman RJ, Watts GF, Puddey IB et al. Leukocyte count and vascular function in Type 2 diabetic subjects with treated hypertension. Athetoscletosis 2002;163:175-81.
8. Zinman B, Hanley AJ, Harris SB, Kwan J, Fantus IG. Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab 1999;84:272-8.
9. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
10. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409-15.
11. Fisher EA, Ginsberg HN. Complexity in the sectetory pathway: the assembly and sectetion of apolipoprotein B-containing lipoproteins. J Biol Chem 2002;277:17377-80.
12. Akanji AO, Abdella N, Mojiminiyi OA. Determinants of glycated LDL levels in nondiabetic and diabetic hyperlipidaemic patients in Kuwait. Clin Chim Acta 2002;317:171-6.
13. Bowie A, Owens D, Collins P, Johnson A, Tomkin GH. Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient? Atherosclerosis 1993;102:63-7.
14. Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 1992;12:1496-502.
15. Graier WF, Kostner GM. Glycated low-density lipoprotein and atherogenesis: the missing link between diabetes mellitus and hypercholesterolaemia? Eur J Clin Invest 1997;27:457-9.
16. Kopprasch S, Pietzsch J, Kuhlisch E et al. In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance. Diabetes 2002;51:3102-6.
17. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated athetogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intetn Med 2001;135:447-59.
18. Taskinen MR. Diabetic dyslipidemia. Atheroscler Suppl 2002;3:47-51.
19. Gerrity RG. The role of the monocyte in atherogenesis. I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol 1981;103:181-90.
20. Boullier A, Bird DA, Chang MK et al. Scavenger receptors, oxidized LDL, and atherosclerosis. Ann N Y Acad Sci 2001;947:214-22.
21. Itabe H, Takano T. Oxidized low density lipoptotein: the occurrence and metabolism in circulation and in foam cells. J Atheroscler Thromb 2000;7:123-31.
22. Mazzone T, Lopez C, Bergstraesser L. Modification of very low density lipoproteins leads to macrophage scavenger receptor uptake and cholesteryl ester deposition. Arteriosclerosis 1987;7:191-6.
23. Steinberg D. At last, direct evidence that lipoxygenases play a role in atherogenesis. J Clin Invest 1999;103:1487-8.
24. Hoppe G, O'Neil J, Hoff HF. Inactivation of lysosomal proteases by oxidized low density lipoprotein is partially responsible for its poor degradation by mouse peritoneal macrophages. J Clin Invest 1994;94:1506-12.
25. Roma P, Bernini F, Fogliatto R et al. Defective catabolism of oxidized LDL by J774 murine macrophages. J Lipid Res 1992;33:819-29.
26. Lougheed M, Zhang HF, Steinbrecher UP. Oxidized low density lipoprotein is resistant to cathepsins and accumulates within macrophages. J Biol Chem 1991;266:14519-25.
27. Hamilton TA, Ma GP, Chisolm GM. Oxidized low density lipoprotein suppresses the expression of tumor necrosis factor-alpha mRNA in stimulated mutine peritoneal macrophages. J Immunol 1990;144:2343-50.
28. Chu X, Newman J, Park B, Nares S, Ordonez G, Iacopino AM. In vitro alteration of macrophage phenotype and function by serum lipids. Cell Tissue Res 1999;296:331-7.
29. Rasmussen LT, Seljelid R. The modulatory effect of lipoproteins on the release of interleukin 1 by human peritoneal macrophages stimulated with beta-1,3-D-polyglucose derivatives. Scand J Immunol 1989;29:477-84.
30. Kiener PA, Davis PM, Murray JL, Youssef S, Rankin BM, Kowala M. Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int Immunopharmacol 2001;1:105-18.
31. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/ CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70.
32. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
33. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
34. Phillips AN, Neaton JD, Cook DG, Grimm RH, Shaper AG. Leukocyte count and risk of major coronary heart disease events. Am J Epidemiol 1992;136:59-70.
35. Kullo IJ, Hensrud DD, Allison TG. Comparison of numbers of circulating blood monocytes in men grouped by body mass index (<25, 25 to <30, > or =30). Am J Cardiol 2002;89:1441-3.